Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
13.81
-0.22 (-1.57%)
At close: Mar 11, 2026, 4:00 PM EDT
13.80
-0.01 (-0.07%)
After-hours: Mar 11, 2026, 4:10 PM EDT
Theravance Biopharma Employees
Theravance Biopharma had 97 employees as of December 31, 2024. The number of employees decreased by 2 or -2.02% compared to the previous year.
Employees
97
Change (1Y)
-2
Growth (1Y)
-2.02%
Revenue / Employee
$828,113
Profits / Employee
$302,515
Market Cap
699.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 97 | -2 | -2.02% | 97 | 0 |
| Dec 31, 2023 | 99 | -12 | -10.81% | 99 | 0 |
| Dec 31, 2022 | 111 | -48 | -30.19% | 111 | 0 |
| Dec 31, 2021 | 159 | -200 | -55.71% | 158 | 1 |
| Dec 31, 2020 | 359 | 43 | 13.61% | 359 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MiMedx Group | 808 |
| ProKidney | 204 |
| Prime Medicine | 146 |
| Lexicon Pharmaceuticals | 103 |
| Tectonic Therapeutic | 60 |
| AgomAb Therapeutics NV | 58 |
| Jade Biosciences | 55 |
| Zura Bio | 30 |
TBPH News
- 8 days ago - Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
- 8 days ago - Theravance plans strategic review, including possible sale, after drug trial failure - Reuters
- 8 days ago - Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions - PRNewsWire
- 3 months ago - Theravance Biopharma, Inc. (TBPH) Discusses Ampreloxetine Phase 3 Program and Unmet Need in Neurogenic Orthostatic Hypotension with Multiple System Atrophy Transcript - Seeking Alpha
- 3 months ago - Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - PRNewsWire
- 4 months ago - Theravance Biopharma to Participate in Upcoming Investor Conferences - PRNewsWire
- 4 months ago - Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire